Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease - Trial NCT06355310
Access comprehensive clinical trial information for NCT06355310 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ann & Robert H Lurie Children's Hospital of Chicago
Timeline & Enrollment
Phase 2
May 20, 2024
Dec 31, 2028
Primary Outcome
Hepatic Fat
Summary
This study is a randomized, double-blind, placebo-controlled trial specifically designed to
 evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for
 treating NAFLD in adolescents with obesity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06355310
Non-Device Trial